Evidence map›Paper›PMID 41459082›Full record

ArticleFrontiers in nutrition2025

Ethnomedicinal validation of

Akingbolabo Daniel Ogunlakin, Gideon Ampoma Gyebi, Amel Elbasyouni, Oyindamola Esther Awosola, Moyosoluwa Mary Dada, Opeyemi Josphine Akinmurele, Abdullahi Adeyemi Adegoke, Israel Kunle Oladoja, Ajibola David Adelakun, Omolola Oluwadara and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Akingbolabo Daniel OgunlakinPhytomedicine and Drug Discovery Research Laboratory (PDD-RL), Biochemistry Programme, Bowen University, Iwo, Nigeria.
Gideon Ampoma GyebiDepartment of Biotechnology and Food Science, Faculty of Applied Sciences, Durban University of Technology, Durban, South Africa.
Amel ElbasyouniDepartment of Molecular Biology and Biotechnology, Pan African University for Basic Sciences, Technology and Innovation (PAUSTI), Nairobi, Kenya.
Oyindamola Esther AwosolaNext Era Pharmacy, Lagos, Nigeria.
Moyosoluwa Mary DadaDepartment of Physiology, Babcock University, Ilisan Remo, Nigeria.
Opeyemi Josphine AkinmureleDepartment of Pharmacognosy, Lead City University, Ibadan, Nigeria.
Abdullahi Adeyemi AdegokeDepartment of Pharmacognosy, University of Ibadan, Ibadan, Nigeria.
Israel Kunle OladojaBiochemistry Department, Ibrahim Badamosi Babangida University, Lapai, Nigeria.
Ajibola David AdelakunDepartment of Pharmaceutical Sciences, University of Arizona, Tucson, AZ, United States.
Omolola OluwadaraProject Development and Design Department, Federal Institute of Industrial Research, Lagos, Lagos State, Nigeria.
Gabriel Olalekan BanwoDepartment of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria.
Adedayo Johnson AdediranDirectorate of Student Support Services, Bowen University, Iwo, Nigeria.
Seun Elizabeth KuyoroBiochemistry Department, University of Massachusetts, Lowell, Lowell, MA, United States.
Adewale Victor AderemiDepartment of Medical Biochemistry, Osun State University, Osogbo, Nigeria.
Oluyomi Stephen AdeyemiPhytomedicine and Drug Discovery Research Laboratory (PDD-RL), Biochemistry Programme, Bowen University, Iwo, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A nutrient-dense vegetable with Ethnomedicinal use for treating oxidative and fibrotic diseases is Methods: Iron chelation, NO scavenging, and DPPH radical scavenging properties of Results and discussion: The extract demonstrated modest antioxidant activity; however, it was less effective than quercetin at scavenging NO radicals, DPPH, and iron-chelating capacity. It demonstrated AChE and MAO inhibition that was dose-dependent, with an IC50 for MAO inhibition of 0.178 ± 0.003 μg/mL that was comparable to donepezil (0.155 ± 0.005 μg/mL). α-Amylase activity increased in a dose-dependent manner, whereas α-glucosidase inhibition remained lower than the control. Testosterone and oestradiol levels in

Indexed as

antifibrotic activitycomputational studyenzyme inhibitionhormone modulationTelfairia occidentalis

Identifiers

PMID41459082
PMCPMC12742219

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.